MOXATAG® Supports Health Education on FamilyDoctor.org
13 10월 2009 - 5:00AM
Business Wire
MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK), the maker of
the first and only FDA-approved once-daily amoxicillin, MOXATAG
(extended-release amoxicillin) Tablets, 775 mg, announced today
that it is supporting educational content on consumer health Web
site FamilyDoctor.org. FamilyDoctor.org was recently named one of
“Five Great Health Sites” on a Newsweek.com blog and one of the
“‘Top Ten’ Most Useful Web Sites” by the Medical Library
Association.
MOXATAG is indicated for the treatment of tonsillitis and
pharyngitis secondary to Streptococcus pyogenes, more commonly
known as strep throat, in patients 12 years and older. MiddleBrook
offers a patient co-pay assistance program for MOXATAG, which
allows most commercially-insured patients to pay no more than $20
for a MOXATAG prescription. The MOXATAG $20 maximum co-pay voucher
can be downloaded at MOXATAG.com and via FamilyDoctor.org.
“We are proud to support FamilyDoctor.org, the only consumer
health web site brought to you by a professional medical
organization, the American Academy of Family Physicians,” said
Frank Koos, senior vice president of sales, marketing and business
development for MiddleBrook Pharmaceuticals. “We are committed to
increasing awareness about appropriate antibiotic usage, and we
commend FamilyDoctor.org for featuring physician-reviewed
information on important health topics such as strep throat.”
About MiddleBrook
Pharmaceuticals:
MiddleBrook Pharmaceuticals, Inc. (Nasdaq: MBRK) is a
pharmaceutical company focused on developing and commercializing
anti-infective products that fulfill unmet medical needs.
MiddleBrook’s proprietary delivery technology—PULSYS—enables the
pulsatile delivery, or delivery in rapid bursts, of certain drugs.
MiddleBrook’s near-term corporate strategy includes improving
dosing regimens and/or reducing frequency of dosing to enhance
patient dosing convenience and compliance for antibiotics that have
been used and trusted by physicians and patients for decades.
MiddleBrook currently markets KEFLEX (cephalexin, USP), the
immediate-release brand of cephalexin, and MOXATAG–the first and
only FDA-approved once-daily amoxicillin. For more information
about MiddleBrook, please visit www.middlebrookpharma.com.
MiddleBrook, MiddleBrook Pharmaceuticals (stylized), MiddleBrook
Pharmaceuticals, Inc. and MOXATAG are our trademarks and have been
registered in the U.S. Patent and Trademark Office or are the
subject of pending U.S. trademarks applications. Each of the other
trademarks, tradenames, or service marks appearing in this document
belongs to the respective holder, as used herein, except as
otherwise indicated by the context.
About MOXATAG:
MOXATAG (amoxicillin extended-release) Tablets, 775mg, is a
once-a-day extended-release formulation of amoxicillin for oral
administration consisting of three components: one
immediate-release component and two delayed-release components. The
three components of MOXATAG are combined in a specific ratio to
prolong the release of amoxicillin compared to immediate-release
amoxicillin. MOXATAG is intended to provide a lower treatment dose,
once-daily alternative to currently approved penicillin and
amoxicillin regimens for the treatment of adults and pediatric
patients 12 years and older with tonsillitis and/or pharyngitis.
For more information about MOXATAG, please visit MOXATAG.com.
Middlebrook Pharmaceuticals (MM) (NASDAQ:MBRK)
과거 데이터 주식 차트
부터 1월(1) 2025 으로 2월(2) 2025
Middlebrook Pharmaceuticals (MM) (NASDAQ:MBRK)
과거 데이터 주식 차트
부터 2월(2) 2024 으로 2월(2) 2025
